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Abstract
Although some studies have shown diversity in HIV integrase (IN) genes, none has focused particularly on the gene evolving
in epidemics in the context of recombination. The IN gene in 157 HIV-1 integrase inhibitor-naı ¨ve patients from the Sa ˜o Paulo
State, Brazil, were sequenced tallying 128 of subtype B (23 of which were found in non-B genomes), 17 of subtype F (8 of
which were found in recombinant genomes), 11 integrases were BF recombinants, and 1 from subtype C. Crucially, we
found that 4 BF recombinant viruses shared a recurrent recombination breakpoint region between positions 4900 and 4924
(relative to the HXB2) that includes 2 gRNA loops, where the RT may stutter. Since these recombinants had independent
phylogenetic origin, we argue that these results suggest a possible recombination hotspot not observed so far in BF CRF in
particular, or in any other HIV-1 CRF in general. Additionally, 40% of the drug-naı ¨ve and 45% of the drug-treated patients
had at least 1 raltegravir (RAL) or elvitegravir (EVG) resistance-associated amino acid change, but no major resistance
mutations were found, in line with other studies. Importantly, V151I was the most common minor resistance mutation
among B, F, and BF IN genes. Most codon sites of the IN genes had higher rates of synonymous substitutions (dS) indicative
of a strong negative selection. Nevertheless, several codon sites mainly in the subtype B were found under positive
selection. Consequently, we observed a higher genetic diversity in the B portions of the mosaics, possibly due to the more
recent introduction of subtype F on top of an ongoing subtype B epidemics and a fast spread of subtype F alleles among
the B population.
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Introduction
In Brazil, BF recombinants have increasing importance in the
HIV epidemic [1,2,3], similar to South America [4], despite
subtype C [5] prevalence in the country’s south region. To date, 9
BF circulating recombinant forms (CRFs) are worldwide recog-
nized, with 6 of them sampled in Brazil (CRF28_BF, CRF29_BF,
CRF38_BF, CRF39_BF, CRF40_BF, and CRF46_BF; www.hiv.
lanl.gov). Also, unique recombinant forms (URFs) are commonly
found [6,7,8]. Currently, there are 4 different antiretroviral
therapies (ARV) for HIV treatment based on: (i) fusion inhibitors
that inhibit conformational changes in the gp41 that are essential
for fusion; (ii) reverse transcriptase (RT) inhibitors, which may be
separated into 2 groups, nucleoside analogs (nucleoside reverse
transcriptase inhibitors [NRTIs]) or non-nucleoside analogs (non-
nucleoside reverse transcriptase inhibitors [NNRTIs]); (iii) prote-
ase (PR) inhibitors; and more recently, (iv) integrase inhibitors such
as raltegravir (RAL) [9] and elvitegravir (EVG) [10]. The integrase
(IN) gene codes for an enzyme responsible for the integration of the
full proviral cDNA in the host chromosome. The HIV-1 IN is a
32-kDa protein with 288 amino acids (aa) expressed together with
a viral PR and RT as the Pol polyprotein and released by PR
cleavage during maturation. This enzyme has 3 distinct functional
domains: the N-terminal domain (NTD; aa, 1–49), catalytic core
domain (CCD; aa, 50–212), and C-terminal domain (CTD; aa,
213–288) [11]. The NTD has a highly conserved zinc-binding
HHCC motif that stabilizes its correct folding. In the CCD, it can
be found a highly conserved acidic motif, D64, D116, and E152,
in all integrases and retrotransposases [11,12]. The last domain,
CTD, binds DNA nonspecifically and plays an important role in
the integration process [13]. Although, the IN gene has become an
important target in the ARV therapy, some mutations in the IN
gene also confer resistance to the integrase inhibitors [14,15].
Brazil started offering free access to HAART treatment in 1996
through the public health system. However, only in the beginning
of 2008, RAL was approved for clinical use in patients who had
HAART failure. Even though there is a large number of patients
under ARV therapy, since the beginning of the epidemic, more
than 217,000 people died as a consequence of AIDS, and over
630,000 might be infected by HIV [16]. The IN gene in Brazilian
patients was previously studied by Passaes et al., 2009 [17] and
Arruda et al., 2010 [18], and major resistance mutations were not
found in integrase inhibitor-naı ¨ve patients, although minor
mutations associated with RAL or EVG resistance were common.
Nevertheless, neither of these previous works addressed the key
aspect of integrase recombination. Our study aimed to sample the
genetic diversity of the IN gene from the most prevalent subtypes
in Brazil, previous to the introduction of RAL in order to evaluate
its recombination profiles and drug resistance mutations in a
population-genetics context, which is relevant to the epidemic in
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e34324the southern cone in particular, and elsewhere in general, once the
Brazilian-borne BF CRFs spread abroad [19].
Methods
Ethics Statements and Clinical samples
This study was submitted to and was approved by the Ethics
Committee on Human Research of the Centro de Refere ˆncia e
Treinamento-DST/AIDS, Sao Paulo, Brazil, and all the patients
signed informed consent terms. Patients were selected from those
sampled and subtyped for parts of the gag, pol and env regions
during the Viral Genetic Diversity Network (VGDN) program
[20]. One hundred fifty-seven HIV-1 samples were obtained from
drug-naı ¨ve and drug-treated individuals; none of which was
treated with integrase inhibitors, from different cities of the Sa ˜o
Paulo State.
DNA Extraction, PCR, and Sequencing
DNA was extracted from the infected PBMCs by using
QIAamp DNA Blood kit (Qiagen, Germany) according to the
manufacturer’s instructions and stored at 280uC until use. The
nested-PCR and sequencing were carried out according to Van
Laethem et al. (2008) [21] (Table S1). PCR products were purified
using QIAquick PCR Purification Kit (Qiagen, Germany).
Sequencing reactions were performed using BigDye
TM Termina-
tor version 3.0 cycle sequencing (ABI PRISMH; PE Applied
Biosystems, Foster City, CA), and the products were analyzed on
ABI 3100 automated DNA sequencers (PE Applied Biosystems,
United States). Sequence data were edited and assembled with the
CodonCode Aligner software (Gene Codes Corporation, United
States). The sequences were submitted to GenBank under the
accession numbers JN234023 to JN234179.
Sequence Analysis
To expand our original dataset we included all the IN sequences
from Brazil available in GenBank. The sequences were analyzed
with the jumping profile hidden Markov model (jpHMM) program
[22,23], which uses detailed information on polymorphism of the
parental populations rather than using individual parental strains
and provides detailed information on the reliability of the
predicted recombination breakpoints [24]. The phylogenetic
analyses were performed using maximum likelihood (ML) as the
optimality criterion. The ML searches were performed using
GARLI v0.951 (Os6GUI) [25] under the general-time reversible
(GTR) model with rates estimated from the data. Only sequences
without recombination evidence within the integrase region were
used for phylogenetic reconstruction. EVG and RAL resistance-
associated mutations and polymorphisms were detected using the
Stanford University HIV Drug Resistance Database [26].
Positive Selection Analysis
Positive selection was determined using the single-likelihood
ancestor counting (SLAC) and fixed-effects likelihood (FEL)
methods implemented in the HyPhy v2.0 [27]. For the subtype
B analysis, a dataset of 324 integrases (126 new sequences and 198
from GenBank); for the subtype F analysis, 80 integrases (17 new
sequences and 63 references); and for subtype C analysis, 53
integrase sequences (1 new sequence and 52 references) were
compiled. Only results with a p-value smaller than 0.05 were
considered. We also compared the average rates of synonymous
substitutions per site between IN genes estimated with SLAC from
different subtypes, as an approximation of the neutral rate of
change. This is justified because it is estimated at codon site
positions that may change with less deleterious impact and make
special sense for the IN genes, which are highly conserved and
expected to have reduced non-synonymous rates due to purifying
selection.
Results
We examined the almost complete IN gene (p31; [864 out of
867 bp] genomic positions 4230–5093 in the HXB2 reference) in
157 patients from different cities in the State of Sa ˜o Paulo, Brazil.
The jpHMM subtyping analysis revealed that 128 integrases
belonged to the subtype B, 17 to the subtype F, 11 to the BF
recombinants (Figure 1), and 1 to the subtype C. To further
confirm the viral subtype, we compared the integrase subtyping
results with those available for other genomic regions. In addition
to the recombinant viruses described above (11/157), another 31
patients were identified as carrying a BF recombinant virus,
despite not having recombinant IN genes. Eight subtype F and 23
subtype B integrases were among the subtype BF genomes.
The Origin of Integrase Recombinants
Since our results indicated that the vast majority of BF
recombinant viruses were not monophyletic (Figure 2), we needed
to consider if they had distinct, independent origins as if emerging
from distinct co-infection events, despite similarities in their
inferred breakpoints. Actually, the high number of URFs, seen in
Figure 2, agreed with the reports on a large number of unique BF
forms in the Brazilian HIV-1 epidemic [3,6,7]. However, 4
samples shared a recombination breakpoint region between
positions 4900 and 4924 (e.g., 0441, 0612, 1426, and 1470)
(Figure 1), which could be explained by a shared evolutionary
history or maybe by the presence of a recombination hotspot in
that particular position in the genome, among other possibilities.
To investigate if these recombinants have a common origin, we
did a phylogenetic analysis on the first 500 nt (recombination-free
segments), including all the subtype B integrases and 8
recombinant integrases (0441, 0612, 0683, 0708, 1005, 1365,
1426, and 1470) that shared this 500-bp region with the subtype B.
Nevertheless, only four of the BF integrase sequences had well
defined breakpoints, but a short F portion of around 150 bp-long,
making them unsuitable for robust phylogenetic inference on the
origin of the F fragments alone. Figure 3 shows that recombinant
sequences dispersed all over the tree as if they had independent
origins. We found the posterior probability of a possible shared
ancestral node for all the recombinants (i.e., testing for monophyly)
to be zero on a set of 5000 plausible trees sampled at stationarity
during 2 independent Markov chain Monte Carlo (MCMC) runs,
each consisting of 20 million steps with the BEAST v1.6.1.
Moreover, we also reconstructed the ‘‘recombinant’’ and ‘‘non-
recombinant’’ states on the same set of plausible trees by using the
symmetric CTMC model for discrete character reconstruction
with BEAST and found that all recombinant states had posterior
probabilities of 0.99 for independent events of transition from
‘‘non-recombinant’’ to ‘‘recombinant’’ nested within the clades of
‘‘non-recombinant’’ integrases with a posterior probability of 1
(Figure 3). We did not find any other HIV CRF genome with a
recombination breaking point at that position. The recurrence of
independently acquired breaking points suggests some sort of
underlying facilitating process at the molecular level. Crucially, the
region where recombination breakpoints had the highest posterior
probabilities converged in 2 loops, comprising a highly structured
viral genomic RNA (gRNA) region [28] (Figure S1) that is prone
to RT stalls and strand transfer during HIV cDNA synthesis
involved in HIV recombination [28].
Brazilian B, F and BF HIV-1 Integrases
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One hundred and thirty-two of the 157 patients (84.08%) had
already been treated with at least 1 drug regimen (mean, 3; up to
13 distinct drug combinations), 85.6% of which were subjected to
HAART. However, none of them received integrase inhibitors.
Forty percent of the drug-naı ¨ve and 45.5% of the drug-treated
patients had at least 1 RAL or EVG resistance-associated amino
acid change, which were values lower than those recently found in
Figure 1. Recombination profiles and selection. Plot of the differences between non-synonymous (dN) and synonymous (dS) rates shown
above in the mosaic maps of integrase (864 bp) with nucleotide sites numbered in relation to the HXB2. Rate values per codon site for the subtype B
(blue squares) and subtype F (green circles). Blue and green striped portions indicate uncertainty on subtype provenance and usually include the
breakpoints (indicated by an asterisk) estimated with jpHMM algorithm available online at the GOBICS server (http://jphmm.gobics.de/jphmm.html).
Samples 0441, 0612, 1365, and 1470 shared the same breakpoint at nucleotide 4924 that falls inside the uncertainty region from 4899 to 4977 bp but
had different recombination profiles on parts of their genomes. Sample 0708 also shared a recombination spot starting at 4899 bp, but no
breakpoint could be determined.
doi:10.1371/journal.pone.0034324.g001
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92Q, 140A/S, 143R/C, 147G, 148H/R/K, and 155H) were
found. Half of the 16 subtype F integrases had minor resistance-
associated mutations. V151I was the most frequent and found to
be present in 65.2% (5/8) of the cases. The polymorphisms
E138D, M154I, and S230N were also found in 1 sample each.
Our single subtype C patient was drug-naı ¨ve and had no
resistance-associated mutation. Likewise, V151I (25%) was the
most common minor resistance mutation among the BF
recombinant integrases, which also had 1 sample sporting
M154I. In the subtype B samples, V151I was also the most
frequent change in 23.3% of the patients. Interestingly, unlike the
F and BF samples, S230N was the second most common mutation,
present in 8.5% of the subtype B sequences. Other B resistance-
associated mutations were L74M (0.8%), T97A (1.6%), E138K
(0.8%), M154I (3.9%), M154L (0.8%), E157K (2.3%), G163R
(3.1%), and I203M (3.1%). The complete list of polymorphisms is
available in Table S2.
Selection Regimen
Figure 1 shows the difference between non-synonymous (dN)
and synonymous (dS) rates at each codon of the IN genes. Positive
values indicate an excess of dN that is indicative of a directional or
positive selection, while negative values indicate codons under
higher dS rates, suggestive of purifying or negative selection. The
extent of the differences indicates the strength of selection. Based
Figure 2. Integrase phylogeny. A maximum likelihood tree for 459 non-recombinant integrase sequences from Brazil (145 generated by us and
314 from other studies) inferred with GARLI v0.95. Thick branches indicate lineages known to be recombinants on other regions of their genomes.
The tree was midpoint rooted, which agrees precisely with the known relationship among HIV-1 group M subtypes [34]. Subtype C sequences are
collapsed for clarity. This tree shows a large number of potential independent origination events of BF recombinants.
doi:10.1371/journal.pone.0034324.g002
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B portions of the mosaics, which is in agreement with the notion of
a more recent introduction of the F on top of a B epidemic,
possibly in concert with a fast spread of F alleles among the B
population. The fact that most of the codon sites of the integrase
had higher dS agrees with its functional relevance for viral
replication revealed by the strong negative selection on deleterious
changes. Nevertheless, several codon sites mainly in the subtype B
were found under positive selection using the SLAC method,
despite the fact that the integrase is relatively conserved compared
to other HIV-1 genes. Some of the positively selected sites, such as
residue 72 in the subtype B and F integrases and residues 151 and
201 in the subtype B, were further confirmed using FEL.
Moreover, the subtype F integrases had 3 additional positively
selected sites at the CCD. Subtype B, on the other hand, presented
many positively selected sites, including residues with important
biological functions, such as the active site loop (aa, 140) [11].
Interaction with human lens epithelium-derived growth factor
(LEDGF/p75; aa: 161, 166, 168, and 171) [29,30], DNA binding
(aa, 163) [30], and the nuclear import signal (aa, 165 and 166)
[31]. At the CTD, positive selection was found only in the subtype
B integrase, including at the DNA binding sites (aa: 230, 234, and
284) [29]. At the NTD, the subtype B and subtype F had 2
positively selected sites (at residues: 17 and 24 and at residues 31
and 45, respectively). Furthermore, the most common BF
integrase recombination profile (breakpoint at residue 232)
preserved the positively selected NTD and CCD domains, and
the subtype F conserved the DNA binding site at CTD. We also
found that the B integrases (dSB=14.4261.88) had a 4.74 times
higher rate of change estimated at silent sites (dS) compared to F
integrases (dSF=3.0460.44) (dSB.dSF, with a probability of 5.9E-
28 of being the same value given a Student’s paired t-test, with a 2-
tailed distribution). This huge difference entails a larger population
size and possibly an earlier entry of the subtype B in our
epidemics. The complete list of positively selected sites is available
in Table S3.
Figure 3. Phylogenetic tree using recombination-free segment. The cladogram summarizes the maximum clade credibility (MCC) tree
including all subtype B integrases and the recombinant integrase sequences sharing the 500 bp subtype B segment. It shows reconstructions in
‘‘recombinant’’ and ‘‘non-recombinant’’ state transitions on a set of 5000 plausible trees by using the symmetric CTMC model for discrete character
reconstruction with BEAST. Recombinant sequences are shown as thick branches, while asterisks at the tips of the MCC tree show sequences that
share a breakpoint at position 4924. Branch lengths only help the visualization of transition events and are not proportional to either quantity of
events or substitution per sites.
doi:10.1371/journal.pone.0034324.g003
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We found that the IN gene of the HIV-1 circulating in the
epidemics in the Sa ˜o Paulo State displayed a diverse plethora of
BF recombinants. Our findings are relevant since not much is
known about the diversity of circulating viruses and their
background resistance-associated polymorphisms in general. The
absence of major integrase resistance mutations in our integrase
inhibitor-naı ¨ve patients, 79% of which were under ARV drugs
such as RT and PR inhibitors, is in line with other studies [17,18]
and justifies the use of this therapeutic strategy. None of the 11
recombinant integrases we found shared the same breakpoints
with the already described BF CRFs from Brazil, although
CRF47_BF from Spain has a breakpoint close to those found in
0441, 0612, 1426, and 1470. These results show the importance of
sequencing different genomic regions for improving HIV subtyp-
ing and give information on the potential of the underestimation of
the real diversity of BF recombinants in our epidemics. Moreover,
we tested the hypothesis that the recombinant genes originated
from a single common ancestral recombination event (testing for
monophyly) by calculating the posterior probability (that was zero)
of monophyly on a set of 5000 plausible trees sampled at
stationarity during 2 independent MCMC runs. We also checked
these results by reconstructing the ‘‘recombinant’’ and ‘‘non-
recombinant’’ states on the same set of plausible trees. This
exercise also reinforced (with posterior probability of 1) the
hypothesis of an independent origin of ‘‘recombinant’’ from ‘‘non-
recombinant’’ states within the clades of ‘‘non-recombinant’’
integrases. Critically, both independent approaches provided
strong statistical support for the notion that the recombinant
sequences we found originated from distinct recombination events.
That being the case and given the fact that the recurrent
recombination region (Figure S2) fell within a secondary gRNA
structural feature known to propitiate recombination, we argue
that it may indicate a potential recombination hotspot, which was
not previously reported for HIV-1 in general and BF recombinants
in particular. Nevertheless, IN is a very conserved region and
therefore prone to recombination [32,33]. Moreover, we cannot
be sure of the extent to which our estimates could have been
influenced by the recombination itself. This is because recombi-
nants with common origin could differentiate later by distinct
subsequent recombination events with divergent parental strains
(i.e., second-generation recombinants). We also observed a 4.7-
times higher accumulation of diversity in the B subtypes compared
to F subtypes in the IN genes. Since there was a reduction in the
number of positively selected sites in the F regions and given that
the most positively selected sites were detected at the B portion of
recombinant forms, we argue that this higher genetic diversity
could be explained by a more recent introduction of F on top of a
B epidemics and a fast spread of F alleles among the larger B
population. It remains to be investigated if the advantage
conferred by the F portions may have to do with the intrinsic F
integrase functionality or adaptive changes acquired following
coinfection.
Supporting Information
Figure S1 Breakpoint region in secondary RNA struc-
ture. Secondary structure of the HIV genomic RNA (gRNA)
numbered according to HXB2. The red region marks the
recombination hotspot from bases 4900 to 4924. Adapted from
Watts J. M. et al. (2009).
(TIF)
Figure S2 Recombination posterior probabilities. Poste-
rior probabilities according to jpHMM of the subtypes for patients
0441 (A), 0612 (B), 1426 (C), and 1470 (D).
(TIF)
Table S1 Primers used for nested amplification of the HIV-1 IN
region from according to Van Laethem K.V. et al. (2008).
(DOC)
Table S2 Complete list of polymorphisms found at integrase
sequences. Minor resistance mutations are shown in red.
(DOC)
Table S3 Positively selected sites in the HIV-1 integrase gene
coding region.
(DOC)
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